ASCO 2018 | Changing the sequence of therapies in prostate cancer: looking ahead

With the positive results from recent trials like SPARTAN (NCT01946204) and PROSPER (NCT02003924), it is likely that drugs typically associated with metastatic castration-resistant prostate cancer (mCRPC), such as enzalutamide and apalutamide, will be shifted forward in treatment strategies to be used in non-metastatic patients. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephane Oudard, MD, PhD, of Georges Pompidou Hospital, Paris, France, discusses the implications such a change would have on the overall treatment landscape of prostate cancer, as well as the role of imaging in establishing treatment plans.